巨噬细胞表型与NLRP3炎症小体组分独立于IL-1介导的组织损伤促进肾钙质沉着相关慢性肾脏病
该研究在高草酸尿小鼠模型中探讨NLRP3炎症小体在肾钙质沉着相关CKD中的作用。NLRP3或ASC缺陷小鼠未能形成肾钙质沉着,而β-羟基丁酸前体1,3-丁二醇抑制NLRP3可保护野生型高草酸尿小鼠免于CKD,但IL-1抑制剂anakinra无效。NLRP3抑制促使肾脏巨噬细胞从促炎/促纤维化表型向抗炎表型转化并防止纤维化,提示NLRP3通过非IL-1依赖机制(包括TGF-β信号和巨噬细胞极化)参与致病。
要点
- NLRP3或ASC缺陷小鼠未能形成肾钙质沉着,限制相关CKD结论。
- 1,3-丁二醇抑制NLRP3可保护高草酸尿野生型小鼠免于肾钙质沉着相关CKD。
- IL-1抑制剂anakinra无效,提示NLRP3作用不依赖IL-1。
核心结论
- 肾钙质沉着相关CKD涉及NLRP3,但并非必须通过肾脏内IL-1释放,而是通过包括TGF-β受体信号和巨噬细胞极化在内的其他生物学功能。
- NLRP3可能是高草酸尿和肾钙质沉着的有希望的治疗靶点。
研究设计与样本
- 研究使用NLRP3缺陷、ASC缺陷及野生型高草酸尿小鼠模型,并以1,3-丁二醇抑制NLRP3、anakinra抑制IL-1进行干预。
- 体外研究使用原代小鼠成纤维细胞确认NLRP3在TGF-β信号通路中的作用。
主要发现
- NLRP3和ASC缺陷小鼠未能形成肾钙质沉着,而高草酸尿野生型小鼠形成严重肾钙质沉着。
- 1,3-丁二醇抑制NLRP3可保护高草酸尿野生型小鼠免于肾钙质沉着相关CKD。
- anakinra抑制IL-1对肾钙质沉着相关CKD无保护作用。
- 1,3-丁二醇抑制NLRP3使浸润肾脏巨噬细胞从促炎(CD45+F4/80+CD11b+CX3CR1+CD206-)和促纤维化(CD45+F4/80+CD11b+CX3CR1+CD206+TGFβ+)表型向抗炎(CD45+F4/80+CD11b+CD206+TGFβ-)表型转化,并防止肾脏纤维化。
- 体外原代小鼠成纤维细胞研究确认NLRP3在TGF-β信号通路中对成纤维细胞活化和增殖具有非冗余作用,且独立于NLRP3炎症小体复合物形成。
临床怎么用
- 在高草酸尿和肾钙质沉着相关CKD中,NLRP3可作为潜在治疗靶点,但IL-1抑制可能无效。
- NLRP3抑制可能通过调节巨噬细胞极化和TGF-β信号减轻肾脏纤维化。
局限性
- NLRP3和ASC缺陷小鼠未能形成肾钙质沉着,限制了对NLRP3在肾钙质沉着相关CKD中作用的结论。
- 研究主要基于小鼠模型和体外原代成纤维细胞,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary/secondary hyperoxalurias involve nephrocalcinosis-related chronic kidney disease (CKD) leading to end-stage kidney disease. Mechanistically, intrarenal calcium oxalate crystal deposition is thought to elicit inflammation, tubular injury and atrophy, involving the NLRP3 inflammasome. Here, we found that mice deficient in NLRP3 and ASC adaptor protein failed to develop nephrocalcinosis, compromising conclusions on nephrocalcinosis-related CKD. In contrast, hyperoxaluric wild-type mice developed profound nephrocalcinosis. NLRP3 inhibition using the β-hydroxybutyrate precursor 1,3-butanediol protected such mice from nephrocalcinosis-related CKD. Interestingly, the IL-1 inhibitor anakinra had no such effect, suggesting IL-1-independent functions of NLRP3. NLRP3 inhibition using 1,3-butanediol treatment induced a shift of infiltrating renal macrophages from pro-inflammatory (CD45+F4/80+CD11b+CX3CR1+CD206-) and pro-fibrotic (CD45+F4/80+CD11b+CX3CR1+CD206+TGFβ+) to an anti-inflammatory (CD45+F4/80+CD11b+CD206+TGFβ-) phenotype, and prevented renal fibrosis. Finally, in vitro studies with primary murine fibroblasts confirmed the non-redundant role of NLRP3 in the TGF-β signaling pathway for fibroblast activation and proliferation independent of the NLRP3 inflammasome complex formation. Thus, nephrocalcinosis-related CKD involves NLRP3 but not necessarily via intrarenal IL-1 release but rather via other biological functions including TGFR signaling and macrophage polarization. Hence, NLRP3 may be a promising therapeutic target in hyperoxaluria and nephrocalcinosis.
引用
- Anders HJ, Suarez-Alvarez B, Grigorescu M, et al. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int. 2017. PMID: 29241624. doi:10.1016/j.kint.2017.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。